Solifenacin + Placebo
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pelvic Organ Prolapse
Conditions
Pelvic Organ Prolapse
Trial Timeline
Mar 1, 2010 → Oct 1, 2011
NCT ID
NCT01092624About Solifenacin + Placebo
Solifenacin + Placebo is a approved stage product being developed by Astellas Pharma for Pelvic Organ Prolapse. The current trial status is terminated. This product is registered under clinical trial identifier NCT01092624. Target conditions include Pelvic Organ Prolapse.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01092624 | Approved | Terminated |
Competing Products
11 competing products in Pelvic Organ Prolapse
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BGS649 + Placebo | Novartis | Phase 2 | 52 |
| Tanezumab + Placebo | Pfizer | Phase 2 | 51 |
| Azithromycin | Pfizer | Phase 3 | 76 |
| Vaginal estrogen + Placebo | Pfizer | Pre-clinical | 22 |
| Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet | Pfizer | Phase 2 | 51 |
| Conjugated Estrogens Cream + Placebo Cream | Pfizer | Approved | 84 |
| BAY1834845 + Placebo | Bayer | Phase 1 | 30 |
| Ofloxacin + Avelox (Moxifloxacin, BAY12-8039) | Bayer | Phase 3 | 74 |
| Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & Metronidazole | Bayer | Phase 3 | 74 |
| Dienogest (BAY86-5258, Visanne) | Bayer | Pre-clinical | 20 |
| Sevoflurane + propofol + remifentanil | Baxter | Approved | 82 |